GB0012209D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0012209D0
GB0012209D0 GBGB0012209.3A GB0012209A GB0012209D0 GB 0012209 D0 GB0012209 D0 GB 0012209D0 GB 0012209 A GB0012209 A GB 0012209A GB 0012209 D0 GB0012209 D0 GB 0012209D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0012209.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9891987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0012209(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0012209.3A priority Critical patent/GB0012209D0/en
Publication of GB0012209D0 publication Critical patent/GB0012209D0/en
Priority to CNB018097812A priority patent/CN100389772C/zh
Priority to BR0110913-8A priority patent/BR0110913A/pt
Priority to JP2001585739A priority patent/JP2004501104A/ja
Priority to ES01935167T priority patent/ES2409033T3/es
Priority to AU6128301A priority patent/AU6128301A/xx
Priority to AU2001261283A priority patent/AU2001261283B2/en
Priority to PCT/US2001/014886 priority patent/WO2001089494A2/en
Priority to EP01935167.5A priority patent/EP1286665B1/en
Priority to CA2409930A priority patent/CA2409930C/en
Priority to US11/594,410 priority patent/US8324189B2/en
Priority to JP2012053573A priority patent/JP2012162531A/ja
Priority to JP2013086245A priority patent/JP2013151553A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0012209.3A 2000-05-19 2000-05-19 Organic compounds Ceased GB0012209D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0012209.3A GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds
CA2409930A CA2409930C (en) 2000-05-19 2001-05-09 Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases
EP01935167.5A EP1286665B1 (en) 2000-05-19 2001-05-09 Treatment regimen of intravenous zoledronate for the treatment of bone metabolism diseases
AU6128301A AU6128301A (en) 2000-05-19 2001-05-09 Method of administering a bisphosphonate
BR0110913-8A BR0110913A (pt) 2000-05-19 2001-05-09 Método de administrar um bisfosfonato
JP2001585739A JP2004501104A (ja) 2000-05-19 2001-05-09 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用
ES01935167T ES2409033T3 (es) 2000-05-19 2001-05-09 Régimen de tratamiento de zoledronate intravenoso para el tratamiento de enfermedades del metabolismo óseo
CNB018097812A CN100389772C (zh) 2000-05-19 2001-05-09 唑来膦酸盐在生产用于治疗骨代谢疾病的药物中的用途
AU2001261283A AU2001261283B2 (en) 2000-05-19 2001-05-09 Use of Zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
PCT/US2001/014886 WO2001089494A2 (en) 2000-05-19 2001-05-09 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
US11/594,410 US8324189B2 (en) 2000-05-19 2006-11-08 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
JP2012053573A JP2012162531A (ja) 2000-05-19 2012-03-09 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用
JP2013086245A JP2013151553A (ja) 2000-05-19 2013-04-17 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0012209.3A GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds

Publications (1)

Publication Number Publication Date
GB0012209D0 true GB0012209D0 (en) 2000-07-12

Family

ID=9891987

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0012209.3A Ceased GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds

Country Status (9)

Country Link
EP (1) EP1286665B1 (cg-RX-API-DMAC10.html)
JP (3) JP2004501104A (cg-RX-API-DMAC10.html)
CN (1) CN100389772C (cg-RX-API-DMAC10.html)
AU (2) AU2001261283B2 (cg-RX-API-DMAC10.html)
BR (1) BR0110913A (cg-RX-API-DMAC10.html)
CA (1) CA2409930C (cg-RX-API-DMAC10.html)
ES (1) ES2409033T3 (cg-RX-API-DMAC10.html)
GB (1) GB0012209D0 (cg-RX-API-DMAC10.html)
WO (1) WO2001089494A2 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture
ES2530791T3 (es) 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
WO2006062876A2 (en) 2004-12-09 2006-06-15 Merck & Co., Inc. Estrogen receptor modulators
DK1930414T3 (da) * 2005-09-08 2012-10-22 Medinet Co Ltd Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle
JP5829400B2 (ja) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
CN102000035B (zh) * 2010-10-13 2012-07-25 江苏奥赛康药业股份有限公司 一种供注射用的唑来膦酸组合物及其制备方法
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2519120C1 (ru) * 2012-11-06 2014-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
BE1021270B1 (nl) * 2014-06-17 2015-10-14 Neogen N.V. Zoledronine oplossing
CN105213407B (zh) * 2015-07-01 2018-01-02 南京大学 唑来膦酸用于制备治疗脂肪性肝病的药物的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate

Also Published As

Publication number Publication date
ES2409033T3 (es) 2013-06-24
JP2004501104A (ja) 2004-01-15
JP2012162531A (ja) 2012-08-30
EP1286665B1 (en) 2013-04-17
WO2001089494A2 (en) 2001-11-29
EP1286665A2 (en) 2003-03-05
WO2001089494A8 (en) 2003-04-17
CA2409930A1 (en) 2001-11-29
WO2001089494A3 (en) 2002-05-23
BR0110913A (pt) 2003-12-30
AU6128301A (en) 2001-12-03
CN100389772C (zh) 2008-05-28
CN1481247A (zh) 2004-03-10
CA2409930C (en) 2012-08-28
AU2001261283B2 (en) 2005-01-13
JP2013151553A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
AU8389101A (en) Organic compounds
GB0010955D0 (en) Organic compounds
GB0006398D0 (en) Organic compounds
GB0001448D0 (en) Organic compounds
GB0008694D0 (en) Organic compounds
GB0003111D0 (en) Organic compounds
GB0008785D0 (en) Organic compounds
GB0002100D0 (en) Organic compounds
AU3458802A (en) Organic compounds
GB0007108D0 (en) Organic compounds
GB0007911D0 (en) Organic compounds
GB0002740D0 (en) Organic compounds
GB0009037D0 (en) Organic compounds
GB0009054D0 (en) Organic compounds
GB0009053D0 (en) Organic compounds
GB0010200D0 (en) Organic compounds
GB0009055D0 (en) Organic compounds
GB0010483D0 (en) Organic compounds
GB0009031D0 (en) Organic compounds
GB0001929D0 (en) Organic compounds
GB0009593D0 (en) Organic compounds
GB0009594D0 (en) Organic compounds
GB0010205D0 (en) Organic compounds
GB0007511D0 (en) Organic compounds
GB0001702D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)